Rhythm Biosciences (ASX:RHY) has reached a pivotal commercial milestone by executing a multi-year supply agreement with US-based Quansys Biosciences.
The deal appoints Quansys as the primary contract manufacturer for ColoSTAT, Rhythm’s blood-based diagnostic test designed for the early detection of colorectal cancer.
The partnership transitions the relationship from a two-year development phase into full-scale commercial production.
Under the agreement, Quansys will utilise its ISO13485-certified facilities to produce consumable reagent kits, providing the scalable capacity necessary to support the upcoming ColoSTAT Access Program and subsequent global rollout.
The contract includes a fixed pricing framework for the first two years, offering Rhythm significant predictability regarding cost of goods and reducing operational risks associated with manufacturing scale-up.